RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

about

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

Item

http://www.wikidata.org/entity/Q35967910

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

@ast

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

@en

type

Item

label

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

@ast

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

@en

prefLabel

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

@ast

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

@en

P1476

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.

@en

P2093

Chunyan Chen

http://www.w3.org/2001/XMLSchema#string

Jihui Jia

http://www.w3.org/2001/XMLSchema#string

Jin Chen

http://www.w3.org/2001/XMLSchema#string

Minran Zhou

http://www.w3.org/2001/XMLSchema#string

Ting Sun

http://www.w3.org/2001/XMLSchema#string

Xiaoming Wang

http://www.w3.org/2001/XMLSchema#string

Xuemei Qin

http://www.w3.org/2001/XMLSchema#string

Yuan Yu

http://www.w3.org/2001/XMLSchema#string

Yue Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences the circadian clock

Acute lymphoblastic leukaemia

The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif

The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells

RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

P304

e0152142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0152142

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27008505

http://www.w3.org/2001/XMLSchema#string

P932

4805198

http://www.w3.org/2001/XMLSchema#string